Tumor extracts from a cohort of SMS-CTR xenografts (HRAS Q61K) demonstrated a decrease in downstream effectors (pMEK, pERK, pS6) via immunoblot, further demonstrating the efficacy of tipifarnib in this cohort (Fig. 4h). The gene discussed is EIF2AK3; the disease is neoplasm.